Sunridge International Makes Further Inroads Into Chinese Market

FOUNTAIN HILLS, Ariz., March 17 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today it had received further orders for its patented Pneumatic Trabeculoplasty (PNT) non-invasive glaucoma treatment in China and said it's exclusive distributor, Beijing Vision World Trading Co. (BV) was moving forward rapidly with a robust nationwide marketing program.

Upon receiving China's State Food and Drug Administration approval last month to market (PNT) equipment and treatment, the company has embarked on an aggressive round of marketing that will embrace several hospitals, health authorities and ophthalmic specialists. Just weeks after placing their initial order for 30 vacuum units and 10,000 rings used in the treatment, Beijing Vision World said that they are placing further orders for an additional 30 units.

Sunridge International's CEO, G. Richard Smith, said that he was delighted with the progress the company was making in China. "We are fortunate to be handled by Beijing Vision World, an aggressive company, in one of the world's largest markets and we are especially pleased to think that our treatment, which has been perfected over a number of years, will soon be put to good use in helping, perhaps, many thousands of glaucoma sufferers in China," he said.

PNT is a safe, efficient and cost effective 2-minute non-invasive alternative treatment for glaucoma and ocular hypertension, that has been developed, patented, and distributed by Sunridge International's wholly owned subsidiary, Ophthalmic International. Further details of the company and its products can be found on the company's website (www.oi-pnt.com).

SOURCE Sunridge International